Articles On Immutep (ASX:IMM)

Title Source Codes Date
ASX Shaken as Gold Miners Reel Amid Global Tensions

Highlights ASX weakened as global risk concerns rose. Gold miners faced broad pressure. Defensive sectors showed relative resilience. The Australian share market ended weaker as global tensions, firmer oil prices, and...

Kalkine Media IMM 1 day ago
Health Check: Cancer assay developer BCAL finds quickest, breast route to the US

BCAL has partnered with the giant Sonic Healthcare to introduce its breast cancer tests to the US market Our drug is no duster, says Immutep Nexalis lands new funding after lender fallout   Breast cancer assay developer BCAL Diagnostics (...

Stockhead IMM 1 day ago
Dr Boreham’s Crucible: A reinvented Racura on the path to commercialisation

Racura executive chair Dr Peter Smith acknowledges investor sentiment towards the local biotech sector is not great, given a string of recent trial setbacks. Not to put too fine a point on it, many of Racura Oncology (ASX:RAC) ASX peers hav...

Stockhead IMM 4 days ago
Short Sellers Circle ASX 200 Stocks as Market Sentiment Shifts

Highlights Short interest stays active across ASX mining and tech shares Rare earth and uranium companies remain under close watch Several ASX consumer and financial stocks attract renewed attention Short selling activ...

Kalkine Media IMM 1 week ago
ASX 200 Slips as Miners Weigh on Market Mood

Highlights Mining shares weakened as copper and gold prices eased. Technology and financial stocks helped cushion the market. Global bond yields and China concerns shaped sentiment. Australian shares ended softer as mi...

Kalkine Media IMM 2 weeks ago
Health Check: Resmed goes out on a limb with its ‘restless leg’ purchase

Sleep apnoea giant Resmed splurges $US360 million ($500m) to buy a company tackling restless leg syndrome April was the cruellest month for ASX biotechs Arovella coup claims more scalps   Having conquered sleep apnoea (snoring), ResMed (...

Stockhead IMM 3 weeks ago
ASX biotechs face final hurdle as Phase III catalysts loom

Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ASX healthcare names now in the high-stak...

Stockhead IMM 4 weeks ago
Biocurious: Stay tuned as drug developers get to the pointy end of their efforts

A gaggle of drug developers is due to disclose company-making clinical study results this year While late-stage clinical trial victory does not confer commercial success, the results tend to be ‘do or die’ In the main, share valuations don...

Stockhead IMM 1 month ago
The Biotech ‘Industrialisation’

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Australian biotechs are successfully turning promising science into a scalable, repe...

FNArena IMM 1 month ago
ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The Bulls N’ Bears ASX Runner of the Week is… Bison Resources, which exploded on debut, as punters piled into its prime Nevada gold-silver projects amid ongoing fuel security chaos.

The West IMM 1 month ago
Closing Bell: ASX falls flat as financials index flips red

ASX crawls just 0.09% higher Financials gives up gains, unwinding market momentum Energy, utilities drag as US-Iran ceasefire continues Market struggles to hold momentum It was relatively quiet on the Middle Eastern front, with no dramati...

Stockhead IMM 1 month ago
ASX 200 Midday Movers: Tech Rises, Energy Slips

Highlights Market edges higher on easing oil prices Tech and gold stocks lead sector gains Energy and banks weigh on sentiment ASX 200 edged higher at midday, driven by gains in technology and gold stocks, while energy and financi...

Kalkine Media IMM 1 month ago
Why this ASX biotech stock just rocketed 89% today

Immutep Ltd (ASX: IMM) shares are having a rare breakout session on Wednesday. After spending most of the year under relentless selling pressure, the biotech stock has suddenly sprung back to life. At the time of writing, Immutep shar...

Motley Fool IMM 1 month ago
Top 10 at 11: ASX creeps higher as US-Iran ceasefire holds

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Stockhead IMM 1 month ago
Dr Boreham’s Crucible: Positive Alzheimer’s portents for Actinogen Medical

Following the clinical trial setbacks from drug developers Opthea, Immutep, Percheron and Argenica Therapeutics, the local sector could really do with a win. Actinogen Medical (ASX:ACW) could be the one to pull the sector out of its funk –...

Stockhead IMM 1 month ago
Health Check: The biotech winners and losers from a messy March of mayhem

The Ides of March weighed down the sector, but green shoots of recovery may make April fools of the naysayers Telix Pharmaceuticals shares led the top end recovery with a 40% gain It’s April – and drug developers with names starting with ‘...

Stockhead IMM 1 month ago
This ASX 200 stock just hit a multi-year low. Here's what's behind the slide

The CAR Group Ltd (ASX: CAR) share price is once again in the red on Friday. At the time of writing, shares are down 1.92% to $22.51, after falling as low as $22.19 earlier in the session. That marks a multi-year low, with the stock now...

Motley Fool IMM 2 months ago
Guess which ASX mining stock is crashing 24% today

Syrah Resources Ltd (ASX: SYR) shares are crashing deep into the red on Friday. In morning trade, the ASX mining stock is down 24% to a multi-year low of 11 cents. Why is this ASX mining stock crashing? Investors have been selling the graph...

Motley Fool IMM 2 months ago
Health Check: Amplia shares almost double on pancreatic cancer trial results

Pancreatic cancer is normally a death sentence, but five patients in Amplia’s studies have emerged tumour free It’s a case of ‘good golly Molly’ as medical pot platform joins the psychedelics push Nexsen wins positive FDA feedback on its p...

Stockhead IMM 2 months ago
ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia

The Bulls N’ Bears ASX Runner of the Week is… Immutep. In a slightly perverse twist, the oncology mid-cap bounced hard from last week’s 90 per cent drop, gaining 53 per cent after a brutal sell-off.

The West IMM 2 months ago
HotList stocks: Northern Star, Immutep, Lodestar, and other trending companies in Week 12

Good afternoon, and welcome to the HotCopper HotList column. Every week, ASX companies of every shape and size go through the ups and downs that is the Australian trading rollercoaster. Fortunes made, and equity lost each time the bourse op...

themarketonline.com.au IMM 2 months ago
The Overnight Report: No Recovery Rally

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Oil first rallied, then retreated. Equities played the opposite card, recovering tow...

FNArena IMM 2 months ago
Existing myleofibrosis drugs can make the condition worse. Syntara Ltd could be about to change that 

In the face of a new war crisis weighing heavily on both equities and economics alike, value hunters (both long- and short-term minded alike) are chasing down new targets for 2026. Listen to the HotCopper podcast for in-depth discussion...

themarketonline.com.au IMM 2 months ago
Thursday’s HotCopper trends: Racura, EVR, Immutep, and other daily topics | March 19

Racura is well out in front on the Australian bourse topic-wise today – and has had the single biggest jump price-wise – even under what has been a brutal Thursday selling day, though it’s followed closely by another healthcare company (a w...

themarketonline.com.au IMM 2 months ago
Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today?

S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) has been on a decidedly wild ride these past four trading days. After entering a trading halt on Monday, 9 March, Immutep shares resumed trading last Friday. And by th...

Motley Fool IMM 2 months ago
Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) has been on a decidedly wild ride these past four trading days. After entering a trading halt on Monday, 9 March, Immutep shares resumed trading last Friday. And by th...

Motley Fool IMM 2 months ago
Market Open: Escalating war in Iran sends traders for hills; oil boils up to $110/Bbl | March 19

ASX today − Yesterday morning, I suggested Australian traders were waiting for a sign before deciding which way to go. Well, just a day later, oil’s boiling up to $110/barrel and the ASX is heading for a -1.71% collapse. Listen to the Ho...

themarketonline.com.au IMM 2 months ago
The Overnight Report: Cautiously Optimistic

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Equities traded modestly higher overnight as cautiously optimistic investors await f...

FNArena IMM 2 months ago
How does Bell Potter rate these ASX healthcare stocks?

Bell Potter has been running the rule over a number of small-cap ASX healthcare stocks this week. Let's see what the broker is saying about these speculative stocks. Immutep Ltd (ASX: IMM) Immutep is a clinical-stage biopharmaceutical comp...

Motley Fool IMM 2 months ago
Closing Bell: ASX rallies back into the green on split St Patrick’s Day RBA hike decision

ASX rises 0.36% after falling into negative territory just before the RBA decision RBA votes to rase cash rate to 4.1% in 5v4 split decision Real estate and gold stocks lead gains RBA hikes rates in split decision The Reserve Bank did exa...

Stockhead IMM 2 months ago
Why this beaten down $9 billion ASX 200 share is now a buy

S&P/ASX 200 Index (ASX: XJO) share CAR Group Ltd (ASX: CAR) is slipping today. Shares in the auto listings company closed yesterday trading for $24.21. In morning trade on Tuesday, shares are swapping hands for $24.04 apiece, down 0.4%...

Motley Fool IMM 2 months ago
Northern Star Resources shares crash 22% in 2 days – These brokers say buy the dip

Northern Star Resources Ltd (ASX: NST) shares have endured an awful past week of trading.  Last Friday, the ASX 200 gold stock fell more than 18%.  This was followed up by a 5.3% drop on Monday. Holders of Northern Star shares wou...

Motley Fool IMM 2 months ago
Closing Bell: One battle after another for the ASX as headwinds take centre stage

ASX casts defensive sectors in leading roles Oil keeps the spotlight while gold loses some shine CBA and ANZ deliver supporting performances on rate-hike expectations   The plot thickens for global markets While the Oscars played out in H...

Stockhead IMM 2 months ago
Buy, hold, sell: Brainchip, CAR Group, and Endeavour shares

Looking for ASX shares to buy after recent market weakness? Well, if you are, let's see what analysts are saying about the popular shares in this article, courtesy of The Bull. Are they buys, holds, or sells? Let's find out: Brainchip Hold...

Motley Fool IMM 2 months ago
ASX 200 Rotation Alert: Defensive Sectors Rise as Gold Weakens

Highlights Defensive sectors attract attention as commodity pressure reshapes market sentiment Energy and consumer staples display resilience in early trading activity Several small-cap companies record notable movement acro...

Kalkine Media IMM 2 months ago
ASX 200 Turbulence: Energy Shock and Gold Slump Stir Markets

Highlights Energy shocks and global tensions are reshaping sentiment across Australian equities Gold and materials counters face renewed pressure amid commodity volatility Select companies gain attention as the market search...

Kalkine Media IMM 2 months ago
Top 10 at 11: ASX rotates into defensive sectors as gold slides

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Stockhead IMM 2 months ago
Guess which ASX All Ords stock is jumping higher today on big Tesla news

The All Ordinaries Index (ASX: XAO) is down 0.3% today, but that's not holding back this ASX All Ords stock. The outperforming stock in question is minerals and technology company Syrah Resources Ltd (ASX: SYR). Syrah Resources shares close...

Motley Fool IMM 2 months ago
What Bell Potter is saying about this fallen ASX 200 gold giant

Northern Star Resources Ltd (ASX: NST) shares have been struggling in recent months. Due to production issues, the ASX 200 gold giant is down 32% from its 52-week high to $21.75. While this is disappointing for shareholders, Bell Potter thi...

Motley Fool IMM 2 months ago
Northern Star Resources shares just crashed – time to buy the dip?

Northern Star Resources Ltd (ASX: NST) shares are in focus this week after the company experienced a historic crash on Friday.  The share price tumbled more than 18% in a single day.  It has now fallen more than 30% since the start of...

Motley Fool IMM 2 months ago
5 things to watch on the ASX 200 on Monday

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week with a small decline. The benchmark index fell 0.15% to 8,617.1 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 200 e...

Motley Fool IMM 2 months ago
ASX Movers Spotlight: Market Leaders and Laggards

Highlights Market activity across the ASX revealed strong divergence among sectors. Defence technology, healthcare, and infrastructure companies led the advancing side. Mining, biotech, and investment firms featured among th...

Kalkine Media IMM 2 months ago
Market Jitters Deepen as ASX Slides Amid Global Tensions

Highlights Rising geopolitical tensions weigh on Australian equities Mining stocks face pressure while energy and defence firms gain attention Banking sector steadies market sentiment amid rate expectations Heightened...

Kalkine Media IMM 2 months ago
Oil Shock Rattles ASX 200 as Mining Giants Weigh on Market

Highlights Oil surge unsettles Australian sharemarket sentiment Mining giants face pressure from rising energy costs Banking stocks display steadier momentum Global energy developments have triggered fresh volatility a...

Kalkine Media IMM 2 months ago
Closing Bell: ASX wobbles to weak finish as energy chaos continues

ASX slips 0.14% on Friday, but ends up 0.17% over the past five days Oil prices remain high, with Brent crude hovering around US$100/barrel Energy stocks rise alongside mining and banking majors   ASX stumbles to week’s end The S&P/AS...

Stockhead IMM 2 months ago
Phase III Shock Sends Immutep Shares Into Steep Slide

Highlights Clinical study halt shakes confidence in biotech pipeline. Lung cancer program setback triggers sharp market reaction. Focus shifts toward remaining research programs. A halted late-stage lung cancer trial h...

Kalkine Media IMM 2 months ago
Scott Power: ASX healthcare sector reels after another tough week

ASX health sector falls about 2.5% for the past five days while broader market is just scraping by as the Middle East conflict takes a toll Immutep plunges 90% on Friday after abandoning its Phase III trial of lung cancer treatment  Pro Me...

Stockhead IMM 2 months ago
HotCopper Highlights Week 11: Immutep scalped; Syrah Trump’s latest victim; Japan’s Lynas handout & more

Good Afternoon, I’m Jon Davidson, it’s a Friday and you know what that means – it’s time for HotCopper Highlights, the segment where we wrap up the stocks and company announcements you were watching and viewing the most this week on Austral...

themarketonline.com.au IMM 2 months ago
The ides of March come for Immutep as lung cancer trial cancellation triggers plummet

Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the speculative trader’s speculative investme...

themarketonline.com.au IMM 2 months ago
Immutep Discontinues TACTI-004 Phase III Trial Due to Futility

SmallCaps IMM 2 months ago